Background
==========

Mismatch repair (MMR) defects characterize 2-4% of colorectal cancers linked to Lynch syndrome and 15% of sporadic colorectal cancers caused by epigenetic *MLH1* promoter methylation. Various strategies can be used to preselect colorectal cancers for MMR protein testing, e.g. clinical guidelines for hereditary cancer, MMR prediction models that combine clinical and pathological information and potentially novel biomarker-based strategies \[[@B1]-[@B5]\].

Universal assessment of immunohistochemical MMR staining is increasingly applied in colorectal cancer diagnostics in order to identify cases suspected of Lynch syndrome for further molecular diagnostics and to obtain treatment-predictive information linked to somatic methylation of *MLH1*\[[@B6]\].

The monoclonal antibodies used for immunohistochemical MMR protein staining generally result in stable and consistent staining patterns with retained staining or loss of staining. Functional interaction between the MLH1/PMS2 and the MSH2/MSH6 proteins implies that the expression pattern of the heterodimerizing protein partner may be used to direct mutation analysis. Aberrant MMR function typically leads to complete loss of nuclear staining in the tumor cells, particularly when linked to *MLH1* promoter hypermethylation that leads to complete gene silencing \[[@B7]\]. In Lynch syndrome, the multitude of disease-predisposing mutations may have variable effects on epitope expression, from complete loss to weak or retained expression for one or both heterodimerizing proteins \[[@B8],[@B9]\]. Variable epitope expression may also result in alternative expression patterns, e.g. cytoplasmic staining and perinuclear staining, which are typically present throughout the tumor \[[@B10]\]. MMR protein immunostainings are generally stable and relatively easy to interpret; though challenges and pitfalls have been reported with false positive as well as false negative interpretations \[[@B10]-[@B12]\]. Most commonly, these observations relate to technical artifacts caused by suboptimal fixation or paraffin-embedding, necrotic areas, sample storage, antibody specificity, clone selection or staining conditions \[[@B13],[@B14]\]. Also, neoadjuvant chemotherapy and radiotherapy may influence the results with a particular effect on MSH2/MSH6 staining \[[@B15],[@B16]\]. Heterogenous expression patterns with retained staining in the adenomatous part and loss of staining in a smaller, invasive part of the tumor have been reported but their relevance is uncertain \[[@B17]\]. We systematically collected colorectal cancers with heterogenous MMR protein staining patterns for detailed analysis with correlations e.g. to MSI status and *MLH1* promoter methylation.

Methods
=======

Materials
---------

Colorectal cancers with heterogenous MMR protein expression were identified during evaluations at the Departments of Pathology, Helsingborg Hospital, Sweden and Hvidore Hospital, Denmark. Following the first observation of heterogenous MMR protein staining in 2007, two gastrointestinal pathologists (PJ and SH) collected all such cases identified at these two institutions during 5 years. In total, 14 colorectal cancers with heterogenous MMR protein expression were identified for in-depth analysis (Table [1](#T1){ref-type="table"}). The materials consisted of resection specimens from 12 colon cancers and 2 rectal cancers. None of the patients had received neoadjuvant radiotherapy or chemotherapy. All cases were histologically re-evaluated by one pathologist (P.J.). Tumor stage was determined according to the American Joint Cancer Committee/Union Internationale Contre le Cancer (AJCC/UICC) staging system and the grade according to the WHO system. Mucinous cancers were considered poorly differentiated. A tumor was classified as mucinous cancer if more than 50% of the tumor area showed such differentiation \[[@B18]\]. Tumors with mucinous components that encompassed &50% of the area were classified as having a mucinous component, though not fulfilling the criteria for mucinous tumors \[[@B19]\]. Mucinous cancer was observed in 6 cases. MMR gene mutation testing had been performed in 8 cases, 4 of which carried disease-predisposing mutations. Ethical approval for the study was granted from the ethical committees at Lund University, Sweden and at the Capital Region, Copenhagen.

###### 

Summary of clinical and pathological data

  **Case**    **Sex/Age**   **Tumor location**   **Histologic type**   **Differentiation**   **pTNM**   **Stage**   **MMR gene mutation**
  ---------- ------------- -------------------- --------------------- --------------------- ---------- ----------- -----------------------
  1              F/57             Cecum                 Adca                Moderate          T2N0MX        I            Not tested
  2              F/33             Cecum             Mucinous adca             Poor            T2N0MX        I              *MSH2*
  4              M/41             Rectum                Adca                Moderate          T3N0MX       II              *MSH6*
  5              F/63        Transverse colon       Mucinous adca           Moderate          T4N1MX       III           Not tested
  6              F/82             Rectum            Mucinous adca           Moderate          T2N0MX        I          Not identified
  8              M/85             Cecum                 Adca                  Poor            T4N0MX       II          Not identified
  9              M/71        Ascending colon        Mucinous adca             Poor            T3N0MX       II            Not tested
  10             F/66        Ascending colon        Mucinous adca             Poor            T3N0MX       II          Not identified
  11             F/57        Descending colon           Adca                Moderate          T3N0MX       II              *MSH6*
  12             F/55        Ascending colon            Adca                  Poor            T3N0MX       II              *MLH1*
  14             M/82        Ascending colon            Adca                Moderate          T3N0MX       II            Not tested
  15             M/83        Ascending colon            Adca                Moderate          T3N0MX       II            Not tested
  16             M/74        Transverse colon       Mucinous adca             Poor            T3N1MX       III           Not tested
  17             F/74             Cecum                 Adca                  Poor            T3N1MX       III         Not identified

*F*: female; *M*: Male; Adca: adenocarcinoma; *MMR*: mismatch repair.

MMR protein immunostaining
--------------------------

Sections from all tumor blocks (n = 4-11) from the 14 cases were subjected to independent MMR protein staining using alternative MMR protein antibodies from other manufacturers (Table [2](#T2){ref-type="table"}). Fresh 4-μm sections from formalin-fixed, paraffin-embedded tumors were mounted on Dako REAL™ Capillary gap microscope slides (Dako, Glostrup, Denmark). The slides were dried overnight at room temperature and thereafter at 60°C for 1--2 hours. The tissue was deparaffinized in xylene for two times 5 min, followed by 5 min each in 99.5% and 95% ethanol and 5 min in distilled water. Heat-induced epitope retrieval was achieved by pressure boiler-treatment in ethylene diamine tetraacetic acid (EDTA)-Tris buffer (1:10 mM, pH 9.0) for 20 min. Hereafter, the slides were cooled for 20 min and rinsed in distilled water. Immunostaining was performed using the Dako Autostainer and the EnVision™ visualization method (Dako, Glostrup, Denmark). Endogenous peroxidase activity was blocked for 5 min and primary mouse monoclonal IgG antibodies were used (Table [2](#T2){ref-type="table"}). Following primary antibody incubation, the slides were incubated with EnVision™/horseradish peroxidase (HRP) rabbit/mouse (Dako) and stained using the EnVision™ Detection System peroxidase/DAB rabbit/mouse (Dako). The immunohistochemical stainings were classified as retained, lost or reduced, i.e. a weaker than expected staining in the tumor cells compared to the stromal cells. The areas of the respective expression patterns were estimated in each block end expressed in percentage.

###### 

Information on the MMR protein antibodies used

  **MMR protein**    **Lab**       **Supplier**        **Clone**   **Dilution**       **Immunogen/epitope**
  ----------------- --------- ----------------------- ----------- -------------- -------------------------------
  MLH1                  L          BD Pharmingen        G168-15       1:100                Full-length
                        C              DAKO              ES05          RTU         Recombinant protein, 210 aa
                        L              DAKO              ES05         1:100        Recombinant protein, 210 aa
  PMS2                  L          BD Pharmingen         A16-4        1:300          aa 431--862, C-terminal
                        H      Ventana (Cell Marque)    EPR3947        RTU             100 aa, C-terminal
                        C            Epitomics          EPR3947        1:50            100 aa, C-terminal
  MSH2                  L           Calbiochem           FE11         1:100                C-terminal
                        H      Ventana (Cell Marque)   G219-1129       RTU                 Full-length
                        C           Novocastra           25D12         1:50                Full-length
  MSH6                  C            Epitomics           EP49         1:100       Synthetic peptide, N-terminal
                        L            Epitomics          EP3945        1:100       Synthetic peptide, N-terminal
                        L      BD Transduction Lab.       44          1:500       Synthectic peptide aa 225-333

*MMR*: mismatch repair; *L*: Lund; H Helsingborg; *C*: Copenhagen; *RTU*: ready to use.

Microsatellite instability analysis
-----------------------------------

To assess the impact from heterogenous MMR protein stainings on MMR protein function, the tumors were subjected analysis of microsatellite instability (MSI). Depending on the extent of the area involved, microdissection or macrodissction was used to obtain material from areas with the respective expression patterns (Table [3](#T3){ref-type="table"}). Laser capture micro-dissection was performed using Polyethylene Teraphthalate (PET)-membrane FrameSlides (Carl Zeiss MicroImaging, Germany). In tumors where larger areas showed variable expression patterns, macro-dissection was performed. Tissue from 2--6 tumor areas with the respective MMR protein stained patterns were collected from 10-μm tissue sections. DNA extraction was performed using QIAamp® DNA micro kit (Qiagen) for laser micro-dissected tissues and using the QIAcube machine (Qiagen) or the QIAamp® DNA FFPE tissue kit (Qiagen) for macro-dissected tissues or whole tumor sections. MSI analyses were performed using the MSI Analysis System, Version 1.2 (Promega, Madison, WI), PCR products were size separated on a 3130*xl* Genetic Analyzer (Applied Biosystems, Foster City, CA). The results were evaluated using the GeneMapper® software Version 4.0 (Applied Biosystems, Foster City, CA). The analysis included the 5 mononucleotide markers BAT-25, BAT-26, NR-21, NR-24, and MONO-27 (Promega, MSI Analysis System, Version 1.2, Madison, WI). Tumors with instability for 1 marker were classified as MSI low, tumors with instability for ≥2 markers were classified as MSI-high (MSI-H), and tumors with stability for all markers were classified as microsatellite stable (MSS).

###### 

Summary of MMR heterogeneity

  **Case**    **Block no**.   **Hetero**-**geneity**   **Pattern**   **Involved area(%)**   **MMR protein immunostaining**   **Fraction of MSI in markers**   **MLH1 promoter methylation**                      
  ---------- --------------- ------------------------ ------------- ---------------------- -------------------------------- -------------------------------- ------------------------------- ----- ------------- -----
  1              1A¤/\*                 \+                 CL                 15                         +/−                              +/−                              \+                 \+    0/5 and 4/5   +/−
                   1B                   \+                 CL                 5                           \-                               \-                              +/R                +/−                   
                   1C                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   1D                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   1E¤                  \+               CL, IG            70 / 10                       +/−                              +/−                              +/R                +/−   0/3 vs 4/5      
  2                24                   \-                  H                 0                           \+                               \+                              \+                 \+                  \-
                  25\*                  \-                  H                 0                           \+                               \+                              \+                 \+        0/5         
                   26                   \-                  H                 0                           \+                               \+                              \+                 \+                    
                  27\*                  \-                  H                 0                           \+                               \+                              \+                 \+        0/5         
                   28                   \+               CL, IG               15                         +/−                              +/−                              \+                 \+                    
                  29\*                  \+               CL, IG               40                         +/−                              +/−                              \+                 \+        5/5         
                   30                   \+                 IG                 10                         +/−                              +/−                              \+                 \+                    
                   31                   \+                 IG                 5                          +/−                              +/−                              \+                 \+                    
                   32                   \+                 IG                 5                          +/−                              +/−                              \+                 \+                    
  4                 2                   \+                 IG                 97                          \+                               \+                              +/−                R/-                 NE
                  3¤/\*                 \+               CL, IG               95                          \+                               \+                              +/−                R/-   3/3 vs 3/5      
                    4                   \+               CL, IG               80                          \+                               \+                              +/−                R/-                   
                   5\*                  \+                 IG                 95                          \+                               \+                              +/−                R/-       5/5         
  5               20\*                  \+               CL, IG            50 / 100                       \+                              +/−                              \-                 R/-       5/5       \-
                   21                   \+                 IG                100                          \+                               \+                              \-                 R/-                   
                   23                   \+                 IG                100                          \+                               \+                              \-                 R/-                   
                   24                   \+                 IG                100                          \+                               \+                              \-                 R/-                   
                   25                   \+               COM, IG             100                          \+                               \-                              \-                 R/-                   
                   26                   \+               COM, IG             100                          \+                               \-                              \-                 R/-                   
                   27                   \+               COM IG              100                          \+                               \-                              \-                 R/-                   
                   28                   \+               COM, IG             100                          \+                               \-                              \-                 R/-                   
                   29                   \+               COM, IG             100                          \+                               \-                              \-                 R/-                   
                   30                   \+               COM, IG             100                          \+                               \-                              \-                 R/-                   
                   31                   \+               COM, IG             100                          \+                               \-                              \-                 R/-                   
  6                5¤                   \+                 IG                100                          \+                              R/-                              \+                 \+    0/5 vs 0/4    NE
                   6\*                  \+                 IG                100                          \+                              R/-                              \+                 \+        0/5         
                   7\*                  \-                  H                 0                           \+                               \+                              \+                 \+        0/5         
                   8\*                  \+                 IG                100                          \+                              R/-                              \+                 \+        0/5         
                   9\*                  \+                 IG                 95                          \+                              R/-                              \+                 \+        0/5         
                   10                   \+                 IG                 95                          \+                              R/-                              \+                 \+                    
                  11\*                  \+                 IG                100                          \+                              R/-                              \+                 \+        0/5         
  8                5\*                  \-                  H                 0                           \-                               \-                              \+                 \+        5/5       \+
                    6                   \+               CL, IG               60                          \-                               \-                              \+                 R/-                   
                    7                   \+                 CL                 20                          \-                               \-                              \+                 +/−                   
                    8                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                    9                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   10                   \+               CL, IG               20                          \-                               \-                              +/R                +/−                   
                   11                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   12                   \+                 CL                 20                          \-                               \-                              +/−                +/−                   
  9                16                   \-                  H                 0                           \+                               \+                              \+                 \+                  \+
                   19                   \-                  H                 0                           \+                               \+                              \+                 \+                    
                  20\*                  \-                  H                 0                           \+                               \+                              \+                 \+        0/5         
                  21\*                  \-                 COM               100                          \-                               \-                              \+                 \+        5/5         
                   22                   \-                  H                 0                           \+                               \+                              \+                 \+                    
                   40                   \-                  H                 0                           \+                               \+                              \+                 \+                    
                   44                   \-                  H                 0                           \+                               \+                              \+                 \+                    
  10                6                   \+                 CL                 50                          \-                               \-                              +/−                +/−                 \+
                    7                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                    8                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   9\*                  \-                  H                 0                           \-                               \-                              \+                 \+        5/5         
                   10                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   11                   \-                  H                 0                           \-                               \-                              \+                 \+                    
  11                3                   \-                  H                 0                           \-                               \-                              \+                 \+                  \+
                    4                   \+               CL, IG               5                           \-                               \-                              +/−                +/−                   
                    5                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   6\*                  \-                  H                 0                           \-                               \-                              \+                 \+        5/5         
                    7                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   8\*                  \+               CL, IG               30                          \-                               \-                              +/R                +/−       5/5         
  12               3\*                  \+                 CL                 5                           \-                               \-                              +/−                +/−       5/5       \+
                    4                   \+               CL, IG               90                          \-                               \-                              +/−                +/−                   
                    5                   \+               CL, IG               80                          \-                               \-                              +/−                +/−                   
                    6                   \-                  H                100                          \-                               \-                              \-                 \-                    
                    7                   \+                 CL                 60                          \-                               \-                              +/−                +/−                   
                    8                   \+               CL, IG               90                          \-                               \-                              +/−                +/−                   
                   9\*                  \+               CL, IG               60                          \-                               \-                              +/−                +/−       5/5         
  14              1A\*                  \-                  H                 0                           \-                               \-                              \+                 \+        5/5       \+
                  1B\*                  \+                 CL                 5                           \-                               \-                              +/R                +/−       5/5         
                  1C\*                  \+               CL, IG               30                          \-                               \-                              R/-                +/−       5/5         
                  1D\*                  \+                 CL                 40                          \-                               \-                              +/R                +/−       5/5         
                  1E\*                  \+               CL, IG               40                          \-                               \-                              R/-                +/−       5/5         
  15              4A\*                  \+                 IG                100                          \+                               \+                              +/R                R/-       5/5       NE
                  4B\*                  \+                 IG                100                          \+                               \+                              \+                 R/-       5/5         
                   4C                   \+                 IG                100                          \+                               \+                              +/R                R/-                   
                   4D                   \+                 IG                100                          \+                               \+                              \+                 R/-                   
                   4E                   \+                 IG                100                          \+                               \+                              +/R                R/-                   
  16               6A                   \+                 IG                 15                          \-                               \-                               R                 +/−                 \+
                  6B\*                  \+                 CL                 3                           \-                               \-                              +/R                +/−       5/5         
                   6C                   \+                 CL                 10                          \-                               \-                              +/R                +/−                   
                   6D                   \+                 IG                 5                           \-                               \-                               R                 +/−                   
                   6E                   \+                 IG                 5                           \-                               \-                              +/R                +/−                   
  17              18\*                  \+                 CL                 55                          \-                               \-                              +/−                +/−       5/5       \+
                   19                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   20                   \+                 CL                 8                           \-                               \-                              +/−                +/−                   
                   21                   \-                  H                 0                           \-                               \-                              \+                 \+                    
                   22                   \-                  H                 0                           \-                               \-                              \+                 \+                    

microdissection; \*: macrodissection; *CL*: clonal, *IG*: intraglandular; *COM*: compartmental; *H*: homogenous; *R*: reduced staining; +/-: heterogenous staining; *MMR*: mismatch repair; *MSI*: microsatellite instability; *NE*: not evaluated.

Methylation-specific PCR analysis
---------------------------------

Extracted DNA was treated with bisulfite using the EZ DNA Methylation-Lightning™ Kit (Zymo Research, CA, USA) according to the manufacturer's instructions. MLH1 promoter methylation status was analyzed by means of a fluorescence-based, real-time methylation-specific PCR assay, as described previously \[[@B20]\]. Two sets of primers and probes, designed specifically for bisulfite-converted DNA, were used: MLH1-M2B for the methylation-specific reaction \[[@B21]\] and ALU-C4 for the methylation independent control reaction used to measure the amount of bisulfite-converted input DNA \[[@B22]\]. Amplification was performed on QuantStudio™ 12 K Flex Real-Time PCR System (Life Technologies). Samples were run in duplicate, including positive and negative controls.

Flow cytometry
--------------

Flow cytometric DNA analysis was performed as previously described \[[@B23],[@B24]\]. The separated cells were then treated with ribonuclease (Sigma-Aldrich, Stockholm, Sweden), incubated with trypsin for 48 h (Merck, Darmstadt, Germany), and stained with propidium iodide (Sigma-Aldrich, Stockholm). Flow cytometric DNA analysis was performed in a FACS Caliber (Becton, Dickinson, BD Biosciences, USA). Up to 20,000 nuclei were analysed from each sample. The DNA histograms obtained were automatically processed using Modfit LT 3.3™ software. The DNA index (DI) was calculated as the ratio of the respective modal channel values of the non-diploid and the diploid G0/G1 peaks. The S-phase fraction (Spf) was estimated assuming that the S-phase compartment constituted a rectangular distribution between the modal values of the G0/G1 and G2 peaks.

Results
=======

Immunohistochemical staining using alternative MMR protein antibodies confirmed heterogenous MMR protein expression in all 14 tumors. Heterogenous expression affected MLH1/PMS2 in 3 tumors, PMS2 in 2 tumors, MSH2/MSH6 in 10 tumors (of which two also expressed heterogeneity for MLH1/PMS2) and MSH6 only in 1 tumor (in which one block also expressed heterogeneity for PMS2). Areas with alternative expression patterns were well demarcated and appeared in three distinct patterns: "intraglandular" (retained/lost staining within or in between glandular formations), "clonal" (retained/lost staining in whole glands or groups of glands) and "compartmental" (retained/lost staining in larger tumor areas/compartments leading to retained/lost staining in between different tumor blocks) (Figure [1](#F1){ref-type="fig"}, Table [3](#T3){ref-type="table"}). Various heterogenous expression patterns co-existed in 9/14 tumors, most commonly as intraglandular and clonal heterogeneity (figure [1](#F1){ref-type="fig"}c). The heterogenous staining patterns were present in 3-100% of the examined tumor area. In 4/14 cases, all tumor blocks showed heterogeneity, whereas the remaining tumors showed heterogeneity in a variable fraction of the tumor blocks (Table [3](#T3){ref-type="table"}).

![**Examples of the different MMR protein staining patterns. A)** clonal loss, **B)** intraglandular loss, **C)** co-existence of clonal and intraglandular loss and **D)** compartmental loss with different patterns in two separate tumor blocks.](1746-1596-9-126-1){#F1}

MSI was demonstrated in 13/14 tumors. Intra-tumor differences in MMR status, i.e.MSI *versus* MSS, in line with MMR protein staining expression was observed in 3 tumors (Table [3](#T3){ref-type="table"}; case 1, 2 and 9). Non-consistent, homogenous MSI status in tumors with heterogenous MMR protein expression was observed in 2 cases (Table [3](#T3){ref-type="table"}; cases 4 and 6). *MLH1* promoter methylation was demonstrated in all 7 cases with complete (non-heterogenic) loss of MLH1/PMS2. In 2 cases (Table [3](#T3){ref-type="table"}; cases 1 and 9) heterogenous MMR protein staining for MLH1/PMS2 correlated with heterogenous *MLH1* promoter methylation, i.e. tumor areas with retained MLH1 expression did not show MLH1 methylation, whereas areas with loss of MLH1 expression showed MLH1 methylation. Concordant immunostaining and methylation status suggest functional intratumoral heterogeneity (Figure [2](#F2){ref-type="fig"}). DNA flow cytometric analysis was performed in one tumor (case 1) and demonstrated differences in DNA content within the heterogenous areas, which had DNA indices of 1.13 and 1.57, respectively (Figure [2](#F2){ref-type="fig"}).

![**An adenocarcinoma(case 1)with 4 different expression patterns and various combinations of heterogeneity**, **loss of MLH1/PMS2 and heterogeneity/retained expression for MSH2/MSH6. A)** clonal loss of MLH1 staining. **B)** MSI corresponding to loss of staining, **C)** MSS corresponding to retained MMR protein staining. Methylation analysis revealed **D)** presence and **E)** absence, respectively, of *MLH1* promoter methylation, which verifies clonal *MLH1* methylation status. Flow cytometric analysis showing different DNA indices, i.e. **F)** 1.13 in the MSI area and **G)** 1.57 in the MSS area.](1746-1596-9-126-2){#F2}

Discussion
==========

Heterogeneous MMR protein expression is a rare phenomenon, but corresponds to differences in MMR status within the tumor and is therefore important to recognize to prevent false-positive or false-negative evaluations. We identified three distinct patterns of heterogeneity, i.e. intraglandular, clonal and compartmental heterogenous MMR protein expression. The different patterns co-existed within the same tumor and the extent of the tumor involved varied. In-depth analysis suggests that multiple causes may apply, e.g. variable epitope expression, expression related to variable differentiation, second hit mutations or methylation in selected tumor clones and possibly influence from factors linked to the tumor microenvironment such as hypoxia and oxidative stress \[[@B25]\].

Intraglandular and/or clonal heterogeneity throughout the tumor, which may be caused by variable epitope expression, was identified in 4 tumors (cases 4, 5, 15 and 16, Table [3](#T3){ref-type="table"}). Homogenous loss of MLH1/PMS2 and heterogenous expression of MSH2/MSH6 was identified in 7 tumors that were consistently MSI and showed *MLH1* promoter methylation (Table [3](#T3){ref-type="table"}). This expression pattern has previously been observed and may relate either to a germline *MSH2*/*MSH6* mutation that allows for partial epitope binding in the presence of somatic *MLH1* methylation or to secondary *MSH2*/*MSH6* inactivation \[[@B25]-[@B27]\]. Heterogenous MLH1 and/or PMS2 expression, suggestive of variable *MLH1* methylation/second hit mutations was observed in 2 tumors (case 2 and 6, Table [3](#T3){ref-type="table"}). Case 1 showed a more complex pattern of MMR protein expression and intra-tumor differences in MSI, *MLH1* promoter methylation and DNA content, suggestive of a tumor composed of two distinct clones (case 1, Figure [2](#F2){ref-type="fig"}).

Variable MMR status did in some tumors correspond to variable differentiation, e.g. mucinous areas (cases 5 and 15), poor differentiation (cases 16 and 17) or adenomatous components (case 2, Figure [3](#F3){ref-type="fig"}). Correlation between MSI status and expression also of other molecular markers has been described \[[@B28],[@B29]\]. Different, through homogenous, MMR protein expression patterns in distinct tumor compartments were observed in a mucinous adenocarcinoma (case 9) with loss of MLH1/PMS2 expression, MSI and *MLH1* methylation in 1/7 tumor blocks that corresponded to an adenomatous tumor component (Figure [1](#F1){ref-type="fig"}d). Sample mix was excluded through histologic review and penta-D marker fragment analysis (data not shown). Homogenous loss/reduced staining of MSH2/MSH6 throughout the tumor and additional loss of PMS2 in 7/10 tumor blocks was observed in a mucinous adenocarcinoma (case 5). This case most likely reflects how the mucinous tumor component progressed in another line than the non-mucinous tumor component. Though compartmental loss of MMR protein expression is rare, this observation motivates thorough evaluation of different tumor compartments, particularly when areas with variable expression are identified.

![**Variable MMR protein expression in relation to tumor differentiation. A)** case 5 with retained expression for PMS2 in a mucinous tumor component and loss of PMS2 expression in a non-mucinous component. **B)** case 2 with clonal and intraglandular heterogeneity for MLH1 in the adenomatous component of the tumor, whereas the remaining tumors showed retained expression for MLH1. **C**-**D)** case 17 with clonal heterogeneity for MLH6 in a poorly differentiated tumor component and homogenous expression in a well-differentiated tumor component.](1746-1596-9-126-3){#F3}

Limitations to our study include analysis based on surgical specimens though biopsy material may produce stainings of better technical quality \[[@B30]-[@B33]\]. At the same time use of biopsy material implies analysis of a restricted tumor area that may not capture areas with alternative expression. Also, information on MMR gene mutation status was not available in all cases. The 4 tumors from Lynch syndrome mutation carriers, however, expressed heterogeneity in between different tumor blocks, which showed homogenous as well as heterogenous loss in clonal and intraglandular patterns. Recognition of so-called "patchy" MMR protein staining has been reported and were also considered herein (Table [3](#T3){ref-type="table"}). This phenomenon differs from the heterogenous staining patterns described herein in that it primarily relates to MSH6 stainings, neoadjuvant treatment \[[@B15],[@B16]\] or represents a weak or cytoplasmic staining rather than the distinct and well-demarcated areas of retained staining and loss of staining described herein.

Conclusions
===========

Our study verifies heterogenous MMR status in a subset of colorectal cancer. Heterogenous MMR protein expression appears in three major forms, which frequently co-exist and correlate to differences in MMR status. We suggest that variable MMR protein staining patterns should be considered and when observed linked to extended analysis in order to ensure correct classification of MMR status.
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=============

MMR: Mismatch repair; MSI: Microsatellite instability; MSI-H: MSI-high; MSS: Microsatellite stable.
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